Del.icio.us
Google
Yahoo MyWeb
Facebook
Key People
Management
Lewis Williams, Executive Chairman & Founder
No bio available. Add a bio.
Gail Maderis, President & CEO
No bio available. Add a bio.
Board of Directors
Lewis Williams
No bio available. Add a bio.
Brian G. Atwood
Mr. Atwood has served as a member of our board of directors since our inception. In 1999, he co-founded and currently serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm. Prior to founding Versant Ventures, Mr. Atwood served as a general partner of Brentwood Associates, a venture capital firm. Mr. Atwood also serves on the boards of directors of several pharmaceutical and biotechnology companies, including Cadence Pharmaceuticals, Five Prime Therapeutics, Helicos BioSciences, Immune Design, OpGen, PhaseRx, Trius Therapeutics, and Veracyte. Mr. Atwood also served on the board of Pharmion Corporation from January 2000 until the company’s acquisition in 2008. Mr. Atwood holds a B.S. in biological sciences from the University of California, Irvine, a M.S. in ecology from the University of California, Davis, and an M.B.A. from Harvard University.
James C. Blair
No bio available. Add a bio.
Brook Byers
Brook Byers is Chairman of the Board of Directors of the OptiMedica® Corporation. He has been closely involved with more than 40 new technology ventures. In 1984, he formed the first Life Sciences venture capital group and led Kleiner, Perkins, Caufield & Byers (KPCB) to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 90 Life Sciences companies which have developed hundreds of products to treat major underserved medical needs.
Mr. Byers is currently on the Board of Directors of eight additional companies, including CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, Nanofluidics and XDx, Inc.. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (Chairman), Hybritech (Chairman), Genprobe, Nanogen, and others. These companies have pioneered the medical uses of molecular biology, monoclonal antibodies, molecular diagnostics and genomics.
Mr. Byers is currently a Board member of the University of California at San Francisco Medical Foundation, the California Healthcare Institute, the New Schools Foundation, Stanford's Bio-X Advisory Council, the Stanford Eye Council, and TechNet. He is Co-Chair of the current five year, $1.4 billion, UCSF Capital Campaign and was formerly a Director of the Entrepreneurs Foundation, the Asian Art Museum in San Francisco, the Stanford Graduate School of Business Advisory Council, That Man May See (UCSF) Vision Research Foundation (Chairman), and the Georgia Tech Advisory Board. Raised in Atlanta, Georgia, Brook graduated with a B.S.E.E. from Georgia Tech and an M.B.A. from Stanford.
Fred Cohen
No bio available. Add a bio.
R. Lee Douglas
No bio available. Add a bio.
Mark McDade
No bio available. Add a bio.
Gail Maderis
No bio available. Add a bio.
Profile
OpinionsNews & Blogs
View All News »- Latest
- Most Popular
- Submit a Story »
FivePrime achieves target discovery milestone with Boehringer Ingelheim
Jan 25, 2008 - 0 comments
Five Prime enters Osteoarthritis and Pulmonary Fibrosis Collaboration with Centocor
Jan 25, 2008 - 0 comments
Mark McDade to join FivePrime Board of Directors
Jan 25, 2008 - 0 comments
Five Prime Therapeutics on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.